EN DE
Watch Jacobio Pharmaceuticals Group Co Lt for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Jacobio Pharmaceuticals Group Co Lt (1167) fair value: what the stock is really worth

As of Nov 13, 2026: fair value (intrinsic value) of Jacobio Pharmaceuticals Group Co Lt stock HK$0.93, price HK$4.52, that is 79.4% below the price, quality 42 out of 100. Rating: strongly overvalued. Calculated from audited financials with one of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare HK · Based in China · ISIN KYG4987A1094

JP Jacobio Pharmaceuticals Group Co Lt logo Thin data Nov 10, 2026

Jacobio Pharmaceuticals Group Co Lt

1167 · HK

Far too expensive (fair value 79% below the price), weak company and falling price: meets none of the 3 rules.

Get notified free when this changes
Highly profitable · 69.5% net margin (TTM) 
Low debt 
Generates free cash flow over the last twelve months 
Ranks above peers (9/12) 
Costs just 6.5 times its yearly profit. 
Quality 42/100 
Moderate moat 57/100
Fair value HK$0.9300 · Strongly overvalued 
Falling price (downtrend) 
Weak Growth (revenue 5y −36.0 %/yr in CNY) 
Thin data 
Watch Jacobio Pharmaceuticals Group Co Lt for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

HK$23.05 HK$1.23 Fair Value HK$0.9300 Jul 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 10, 2026.

How to read this chart

60‑month range HK$1.23 – HK$23.05 · fair‑value band HK$0.6200 – HK$1.17 · the HK$4.52 price screens above the HK$0.9300 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 10, 2026.

Follow Jacobio Pharmaceuticals Group Co Lt in your weekly email

Every Wednesday you see whether Jacobio Pharmaceuticals Group Co Lt is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Jacobio Pharmaceuticals Group Co., Ltd., an investment holding company, engages in the in-house discovery and development of oncology therapies in the People's Republic of China.

Show moreShow less

The company develops sitneprotafib (JAB-3312), an oral allosteric SHP2 inhibitor that is in a Phase III trial for non-small cell lung cancer (NSCLC); glecirasib (JAB-21822), a KRAS G12C allosteric inhibitor in Phase II trials for NSCLC, multi-tumor basket, and colorectal cancer; JAB-8263, a BET inhibitor that is in a Phase IIa trial for solid tumors and hematologic malignancies; JAB-BX102, a humanized monoclonal antibody against CD73, which is in a Phase I/IIa trial; JAB-2485, a highly selective Aurora Kinase A (AURKA) inhibitor that is in a Phase I/IIa trial for solid tumors; JAB-23E73, an oral small-molecule pan-KRAS inhibitor that is in a Phase I trial for KRAS-mutant PDAC, CRC, NSCLC, and solid tumors; and JAB-30355, a bioavailable small molecule p53 reactivator that is in a Phase I trial for the treatment of patients with locally advanced or metastatic solid tumors.

It is also developing IND-enabling candidates, including JAB-BX467, JAB-BX600, and JAB-BX700 for solid tumor indications.

The company has a collaboration agreement with AstraZeneca AB to develop and commercialize JAB-23E73. Jacobio Pharmaceuticals Group Co., Ltd. was founded in 2015 and is headquartered in Beijing, China.

Stock analysis

Jacobio Pharmaceuticals Group Co Lt (1167) currently trades at HK$4.52, while our model-based Fair Value estimate is HK$0.9300, 79% below the price, so the stock looks overvalued today.

Show more

Valuation

How firm this estimate is: it rests on 1 models at a data quality of 96/100, which puts the data coverage at low.

Scenario range: HK$0.6200 (bear) to HK$1.17 (bull), the price of HK$4.52 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 42/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.

Jacobio Pharmaceuticals Group Co Lt reported revenue of 52.1M CNY in FY2025 versus 153M CNY in FY2021, a compound −23.6%/yr. Reported net income was −142M CNY in FY2025.

Key figures

Market cap HK$3.5B (≈ $448M) Small · P/E ratio 6.5 · P/S ratio 4.94 · Return on equity 46.3% · Return on assets (EBIT) −19.5% (5-year average) · Operating margin 85.0% · Revenue growth (YoY) +15.0% · Free cash flow −187M CNY.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 57 out of 100 (medium confidence).

What moves the price

The share trades about 50% below its 52-week high and 10% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −5% fair-value upside, at −79%, 1167 screens richer than that median.

Fair Value models

Bear HK$0.6200 Fair Value HK$0.9300 Bull HK$1.17
Price HK$4.52 · Downside -79.4%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
NCAV (Graham) HK$0.6200 HK$0.9300 HK$1.17 54
All 1 models by family
Asset-Based
NCAV (Graham) HK$0.6200 HK$0.9300 HK$1.17 54

Open the full fair value analysis →

Quality Score breakdown

Overall quality 42/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 1
How much profit the company makes from its sales and capital
Quality Growth 14
Are margins and returns getting better?
Cashflow 18
Do the profits arrive as real cash?
Financial strength 71
Debt, balance sheet and risk of trouble
Investment 100
Does it invest with discipline instead of growing at any price?
Low Volatility 50
How calm the share price moves, does not count
Price momentum 17
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 4
Distance to the 52-week high, does not count
New shares 78
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 13/100
Revenue is shrinking: the last year, the last three and the last five years are all negative.
Revenue growth 1 year
−66.5%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−18.3%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−36.0%
Start year 2020 (pandemic)
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−209.0% (2021) → −317.8% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

1167 screens overvalued: fair value 79% below the price. Compare with Vertex Pharmaceuticals Incorporated →

Compare Jacobio Pharmaceuticals Group Co Lt with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 853 stocks

Beats the industry median on 9/12 measures
Overall it ranks above its industry peers.
Valuation
Quality Score 42 · Above median
Fair Value upside −79.4% · Bottom 25%
Profitability
Return on equity (12 months) 46.3% · Top 25%
Return on assets −10.9% · Above median
Net margin (12 months) 69.5% · Top 25%
Operating margin (12 months) 85.0% · Top 25%
Growth and dividend
Revenue growth (quarter YoY) 15.0% · Above median
Balance sheet
Debt / equity 0.12× · Above median

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/E (12 months) 6.5× · Cheapest 25%
P/B 3.87× · Pricier than median
P/S (12 months) 4.04× · Cheaper than median
EV/EBITDA 4.0× · Cheapest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 0
FUTURE (revenue growth)75 · sector 0
PAST (return on equity)100 · sector 0
HEALTH (low debt)94 · sector 96
DIVIDEND (yield)0 · sector 20

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Regeneron Pharmaceuticals, Inc REGN $955.47 $1,275 +33% vs 1167
Genmab A/S GMAB kr 3,448 kr 3,917 +14% vs 1167
Vertex Pharmaceuticals Incorporated VRTX $538.60 $592.46 +10% vs 1167
Samsung Biologics Co 207940 1,411,000 KRW 1,552,100 KRW +10% vs 1167
argenx SE ARGX $960.04 $908.40 −5% vs 1167
CSL Limited CSL A$202.92 A$183.54 −10% vs 1167
Moderna, Inc MRNA $223.37 $139.99 −37% vs 1167
BeOne Medicines AG 6160 HK$249.80 HK$152.80 −39% vs 1167
Celltrion, Inc 068270 214,000 KRW 74,945 KRW −65% vs 1167
Royalty Pharma plc RPRX $69.31 $19.01 −73% vs 1167

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low StocksStocks for 2027: Large Companies Below Fair Value

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Average Down CalculatorFree calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Jacobio Pharmaceuticals Group Co Lt: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Jacobio Pharmaceuticals Group Co Lt Fair Value". https://www.fairvalue-calculator.com/stock/1167

Frequently asked questions

Is Jacobio Pharmaceuticals Group Co Lt (1167) overvalued or undervalued?
As of Nov 10, 2026, our model estimates a fair value of HK$0.9300 versus a price of HK$4.52, about 79% lower (overvalued).
What is the fair value of 1167?
Our model-based fair value for Jacobio Pharmaceuticals Group Co Lt is HK$0.9300 (as of Nov 10, 2026), built from audited fundamentals. The current price: HK$4.52.
What is the quality score of 1167?
Jacobio Pharmaceuticals Group Co Lt has a Quality Score of 42/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Jacobio Pharmaceuticals Group Co Lt (1167)?
Our model-based price target is the fair value of HK$0.9300 (as of Nov 10, 2026) from 1 valuation models. Cautious scenario HK$0.6200, optimistic scenario HK$1.17. It is a calculation from audited fundamentals, not an analyst target.
What is the Jacobio Pharmaceuticals Group Co Lt stock forecast for 2026?
Our models put fair value at HK$0.9300, about 79% lower versus a price of HK$4.52 (overvalued). Cautious scenario HK$0.6200, optimistic scenario HK$1.17. The calculation is refreshed regularly with new filings.
What is the intrinsic value of Jacobio Pharmaceuticals Group Co Lt (1167)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Jacobio Pharmaceuticals Group Co Lt it is HK$0.9300 per share (as of Nov 10, 2026), against a price of HK$4.52. It is the blended result of 1 valuation models in 1 family (Asset-Based).
Is Jacobio Pharmaceuticals Group Co Lt stock overvalued or undervalued in 2026?
As of Nov 10, 2026, 1167 trades above its calculated fair value: price HK$4.52, fair value HK$0.9300, a gap of about −79% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 1167?
No. The price is what the market pays today (HK$4.52); the fair value is what the company's own numbers justify (HK$0.9300). For Jacobio Pharmaceuticals Group Co Lt the two are HK$3.59 per share apart. That gap is exactly why we show both numbers side by side.
How much is Jacobio Pharmaceuticals Group Co Lt worth?
The market values Jacobio Pharmaceuticals Group Co Lt at about HK$3.5B (market capitalisation, as of Nov 10, 2026). Per share that is HK$4.52; our models calculate a fair value of HK$0.9300 per share.
What do the bullish and bearish scenarios say about 1167?
Our models span a range for Jacobio Pharmaceuticals Group Co Lt: cautious scenario HK$0.6200, base HK$0.9300, optimistic HK$1.17 per share (as of Nov 10, 2026, price HK$4.52). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 1167?
Jacobio Pharmaceuticals Group Co Lt trades at a price-to-earnings ratio of 6.5 (as of Nov 10, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of HK$0.9300 is built from several models across several years. Other multiples: P/B 3.9, P/S 4.0, EV/EBITDA 4.0.
How solid is the balance sheet of Jacobio Pharmaceuticals Group Co Lt (1167)?
Balance-sheet figures for Jacobio Pharmaceuticals Group Co Lt (as of Nov 10, 2026): return on equity 46.3%, debt of 0.12 per unit of equity. They feed the Quality Score of 42/100, which measures business quality independently of the share price.
How far is 1167 from its 52-week high?
Jacobio Pharmaceuticals Group Co Lt trades at HK$4.52, about 50% below its 52-week high of HK$9.11 and 10% above the low of HK$4.12 (as of Nov 13, 2026). Distance from the high says nothing about value: that is what the fair value of HK$0.9300 is for.
Which stocks are comparable to Jacobio Pharmaceuticals Group Co Lt?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Moderna, Inc, Regeneron Pharmaceuticals, Inc, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Jacobio Pharmaceuticals Group Co Lt stock attractive at the current price?
The data as of Nov 10, 2026: price HK$4.52, calculated fair value HK$0.9300 (−79%), Quality Score 42/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 1167 calculated?
We run Jacobio Pharmaceuticals Group Co Lt through 1 models from 1 family: Asset-Based. Every model gets the same audited fundamentals; the fair value of HK$0.9300 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.1% above its aggregate fair value. Jacobio Pharmaceuticals Group Co Lt itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Jacobio Pharmaceuticals Group Co Lt (1167)?
The closing price on Nov 13, 2026 was HK$4.52. Our model-based fair value is HK$0.9300, about 79% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Jacobio Pharmaceuticals Group Co Lt right now?
The price sits above even our optimistic bull case (HK$1.17). The favourable scenario is already priced in. Weak quality (42/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range (HK$0.6200 to HK$1.17) leaves room in how you read the outcome.

Key figures of Jacobio Pharmaceuticals Group Co Lt

How large is the market capitalisation of Jacobio Pharmaceuticals Group Co Lt (1167)?
The market capitalisation of Jacobio Pharmaceuticals Group Co Lt is HK$3.5B (≈ $448M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Jacobio Pharmaceuticals Group Co Lt (1167)?
The price-to-sales ratio of Jacobio Pharmaceuticals Group Co Lt is 4.94 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the return on equity of Jacobio Pharmaceuticals Group Co Lt (1167)?
The return on equity (ROE) of Jacobio Pharmaceuticals Group Co Lt is 46.3% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Jacobio Pharmaceuticals Group Co Lt (1167)?
On an EBIT basis the return on assets of Jacobio Pharmaceuticals Group Co Lt is −19.5% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Jacobio Pharmaceuticals Group Co Lt (1167)?
The operating margin of Jacobio Pharmaceuticals Group Co Lt is 85.0% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Jacobio Pharmaceuticals Group Co Lt (1167)?
Revenue at Jacobio Pharmaceuticals Group Co Lt is growing 15.0% versus a year earlier (3y avg −18.3%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Jacobio Pharmaceuticals Group Co Lt (1167) generate?
The free cash flow of Jacobio Pharmaceuticals Group Co Lt is −187M CNY (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Jacobio Pharmaceuticals Group Co Lt (1167) hold?
Jacobio Pharmaceuticals Group Co Lt holds more cash than debt, 778M CNY net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Jacobio Pharmaceuticals Group Co Lt in the live analysis

One click puts Jacobio Pharmaceuticals Group Co Lt on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.